- Home
- All Stock List
- BSE
- Strides Pharma Science Ltd Share Price
811.25
29.45 (3.77%)
-
Outperforms Index
121.3%
Return (1Y)
Beaten BSE Healthcare by 101.79%
-
More Volatile
3.06%
Standard Deviation (1Y)
Higher than BSE Healthcare by 1.99%
-
Consistent Performer
9/12
Months
beaten BSE Healthcare
-
AxisDirect View
No View
795
301
News & Announcements
-
Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Strides Pharma Science consolidated net profit rises 352.09% in the March 2025 quarter
22 - May - 2025 12:00 | 10 days ago
Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1190.39 1043.50 14 4565.34 3890.13 17 OPM % 18.30 16.23 - 17.58 13.58 - PBDT 182.66 84.69 116 614.52 287.89 113 PBT 133.80 36.76 264 422.26 74.25 469 NP 82.19 18.18 352 3593.46 -70.62 LP Powered by Capital Market - Live News
-
-
Strides Pharma Science consolidated net profit rises 352.09% in the March 2025 quarter
22 - May - 2025 12:00 | 10 days ago
Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1190.39 1043.50 14 4565.34 3890.13 17 OPM % 18.30 16.23 - 17.58 13.58 - PBDT 182.66 84.69 116 614.52 287.89 113 PBT 133.80 36.76 264 422.26 74.25 469 NP 82.19 18.18 352 3593.46 -70.62 LP Powered by Capital Market - Live News
-
-
Strides Pharma?s US arm acquires four drugs to bolster portfolio
30 - Apr - 2025 12:00 | 32 days ago
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.
Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.
The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore).
Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products
The company?s consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24.
The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.
Powered by Capital Market - Live News
-
Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Strides Pharma Science consolidated net profit rises 352.09% in the March 2025 quarter
22 - May - 2025 12:00 | 10 days ago
Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1190.39 1043.50 14 4565.34 3890.13 17 OPM % 18.30 16.23 - 17.58 13.58 - PBDT 182.66 84.69 116 614.52 287.89 113 PBT 133.80 36.76 264 422.26 74.25 469 NP 82.19 18.18 352 3593.46 -70.62 LP Powered by Capital Market - Live News
-
-
Strides Pharma?s US arm acquires four drugs to bolster portfolio
30 - Apr - 2025 12:00 | 32 days ago
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.
Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.
The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore).
Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products
The company?s consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24.
The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.
Powered by Capital Market - Live News
-
Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Strides Pharma Science consolidated net profit rises 352.09% in the March 2025 quarter
22 - May - 2025 12:00 | 10 days ago
Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1190.39 1043.50 14 4565.34 3890.13 17 OPM % 18.30 16.23 - 17.58 13.58 - PBDT 182.66 84.69 116 614.52 287.89 113 PBT 133.80 36.76 264 422.26 74.25 469 NP 82.19 18.18 352 3593.46 -70.62 LP Powered by Capital Market - Live News
-
-
Strides Pharma Science consolidated net profit rises 352.09% in the March 2025 quarter
22 - May - 2025 12:00 | 10 days ago
Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1190.39 1043.50 14 4565.34 3890.13 17 OPM % 18.30 16.23 - 17.58 13.58 - PBDT 182.66 84.69 116 614.52 287.89 113 PBT 133.80 36.76 264 422.26 74.25 469 NP 82.19 18.18 352 3593.46 -70.62 LP Powered by Capital Market - Live News
-
-
Strides Pharma?s US arm acquires four drugs to bolster portfolio
30 - Apr - 2025 12:00 | 32 days ago
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.
Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.
The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore).
Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products
The company?s consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24.
The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.
Powered by Capital Market - Live News
Stock Trivia
Strides Shasun Ltd is trading very close to its All time High
Promoter shareholding in Strides Shasun Ltd has increased by 5.49% since past 3 Months
Strides Shasun Ltd is trading very close to its All time High
Strides Shasun Ltd is trading very close to its 52 Week High
MF shareholding in Strides Shasun Ltd has decreased by -18.16% since past 3 Months
Promoter shareholding in Strides Shasun Ltd has increased by 5.49% since past 3 Months
Strides Shasun Ltd is trading very close to its All time High
Promoter shareholding in Strides Shasun Ltd has increased by 5.49% since past 3 Months
